나이아신아마이드 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the niacinamide market size is expected to grow from USD 1.19 billion in 2025 to USD 1.29 billion in 2026 and is forecast to reach USD 1.98 billion by 2031 at 8.85% CAGR over 2026-2031.

This report is Segmented by Form (Powder, Granular, Liquid), by Grade (Pharmaceutical Grade, Feed Grade, and More), by Application (Cosmetics and Personal Care, Pharmaceuticals, and More), by End User (Pharmaceutical Companies, Cosmetic Manufacturers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Niacinamide Market Trends and Insights

Expanding Dermatology-Backed Skincare Adoption

The Niacinamide market is benefiting from stronger dermatology support because the ingredient is no longer treated as a simple vitamin additive in skincare. A 2025 randomized trial in Dermatology and Therapy also supported niacinamide use for preventing post inflammatory hyperpigmentation in skin of color populations, which broadens the clinical relevance of the ingredient across more consumer groups. That combination of barrier support, pigment management, and broad patient relevance helps the Niacinamide market retain formulation space even as other actives receive strong marketing attention. The Niacinamide market is also supported by regulatory familiarity in cosmetics, which lowers reformulation risk for brands and makes supplier qualification more straightforward. As brands build lines around clinically recognized actives, the Niacinamide market gains from repeat use in serums, moisturizers, sunscreens, and adjacent personal care formats.

Growth in Pharmaceutically Positioned Niacinamide Use

The Niacinamide market is also being supported by its role in more pharmaceutically positioned applications, where buyers place greater weight on compliance, purity, and supply assurance. The analysis indicates growth beyond traditional deficiency treatment into NAD+-related uses, oncology support settings, and prescription dermatology, increasing the value profile of pharmaceutical-grade material within the niacinamide market. This trend matters because pharmaceutical demand typically supports stronger pricing discipline than mass cosmetic or feed channels, especially when supplier approval requires cGMP status and batch documentation. As a result, the niacinamide market is showing a clearer split between commodity output and higher-specification supply for regulated or closely supervised applications. The need for traceable distribution channels and better-qualified manufacturers further reinforces this split as downstream buyers move away from generic sourcing. Overall, pharmaceutical positioning supports both demand depth and a more defensible premium tier in the niacinamide market.

Price Pressure from Commodity-Grade Producers

The niacinamide market faces pressure as supply remains concentrated in commodity-grade output, with producers competing primarily on price. This trend is most evident in feed-grade and standard cosmetic-grade supply, where margin protection remains weaker, and any downturn in demand can quickly renew pricing pressure across the niacinamide market. This is also why mid-scale producers face a harder position than either very large Chinese suppliers or better differentiated premium-grade manufacturers. A major sign of this pressure was DSM-Firmenich's February 2026 agreement to divest its Animal Nutrition and Health business, including vitamins, to CVC Capital Partners for an enterprise value of EUR 2.2 billion, which signals less appetite among European majors for lower margin vitamin exposure. The Niacinamide market, therefore, has a clear commodity segment where price recovery can remain fragile even when broader demand looks solid. That pressure keeps procurement teams focused on scale, cost stability, and the risk of supplier concentration in lower-value segments.

Other drivers and restraints analyzed in the detailed report include:

1. Food Fortification and Nutraceutical Label Expansion
2. Capacity Expansion in Asia-Based Manufacturing Clusters
3. Formulation Stability and pH Compatibility Constraints

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Powder held 52.76% of market value in 2025, which makes it the core volume format in the Niacinamide market because it fits established manufacturing routines across pharmaceuticals, nutraceuticals, and food processing. Its position is supported by long shelf life, easy blending, and compatibility with tablet compression and spray dry encapsulation systems used at scale. Granular form remained a secondary format and stayed more relevant in feed applications where dust-free handling is useful in large volume mixing. Liquid form was smaller in current volume terms, but it is forecast to grow at a 9.77% CAGR through 2031 as the Niacinamide market shifts toward more precise cosmetic and injectable uses. That growth profile shows that value expansion in the Niacinamide market is not always coming from the dominant format, but often from the one that solves more specialized formulation needs.

Liquid form is gaining importance because serum and solution-based products need consistent dissolution and tighter concentration control than many powder systems provide. This is especially relevant as brands pursue cleaner formulas and minimal excipient designs, where direct liquid incorporation can reduce processing steps and lower the chance of batch inconsistency. The 2026 liposomal delivery work in the Journal of Pharmaceutical Innovation also supports the longer-term appeal of liquid phase systems for advanced dermatological use, since better carrier design can improve permeation and ingredient stability. Granular material should remain useful where handling efficiency matters more than premium formulation performance, but it is less central to where the Niacinamide market is creating value. In that sense, the Niacinamide market is likely to keep powder as the anchor format while allowing liquid to capture the higher growth lane.

Pharmaceutical grade held 38.13% of the market value in 2025, which gave it the largest grade position and established an important volume floor for the Niacinamide market. Its role is supported by both established therapeutic use and newer research interest linked to NAD+ related applications, which helps maintain demand beyond basic deficiency treatment. This segment also benefits from the fact that cGMP compliance and documentation create practical entry barriers, so qualified supply is not as easily replaced as commodity output. Feed grade still absorbed meaningful tonnage, but it sat at the lowest end of pricing and contributed less to value protection across the Niacinamide market. That makes pharmaceutical grade important not only for current size, but also for holding a more stable pricing position inside the Niacinamide market.

Cosmetic grade is the fastest-growing grade and is projected to expand at a 10.23% CAGR through 2031, which shows where much of the premium value shift is occurring. Buyers in this segment place more weight on residual controls, purity certificates, origin claims, and audit-ready documentation than on volume alone. That preference matters because the Niacinamide market is increasingly rewarding suppliers that can serve brand-level differentiation rather than only bulk ingredient demand. The analysis also indicated stronger demand for biosynthetic origin credentials and sustainability records, which helps explain why premium cosmetic supply can outperform ordinary material, even when overall volumes are smaller. The niacinamide market, therefore, appears increasingly two-tiered by grade, with pharmaceutical supply preserving the base and cosmetic grade driving stronger value uplift.

Complete Report Scope:

• By Form
  • Powder
  • Granular
  • Liquid
• By Grade
  • Pharmaceutical Grade
  • Feed Grade
  • Food Grade
  • Cosmetic Grade
• By Application
  • Cosmetics and Personal Care
    • Skincare Products
    • Haircare Products
  • Pharmaceuticals
    • Vitamin Deficiency Treatment
    • Cardiovascular Support
  • Food and Beverages
  • Human Nutrition
  • Animal Nutrition
• By End User
  • Pharmaceutical Companies
  • Cosmetic Manufacturers
  • Food and Beverage Companies
  • Nutraceutical Companies
  • Animal Feed Producers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific held 42.15% of the Niacinamide market size in 2025, which kept it as the largest regional block in the Niacinamide market. Its lead comes from the combination of production depth and broad downstream consumption across cosmetics, nutrition, and pharmaceutical uses. The region also benefits from a supply base that ranges from commodity volume to more qualified premium output, which allows it to serve several tiers of the Niacinamide market at once. China remains central to this structure, as industry sources identify it as the leading production hub and a major source of cost-competitive supply. South Korea and Japan play a different role, driving demand for high-purity materials used in dermatology-linked and prestige skincare channels.

That combination gives Asia-Pacific a dual advantage in the Niacinamide market because it supports both manufacturing scale and premium demand formation. North America is the fastest-growing geography and is projected to expand at a 9.69% CAGR through 2031, which reflects strong momentum in clinical skincare, supplements, and pharmaceutical compounding demand. The U.S. regulatory environment is becoming more important in supplier selection because implementation activity tied to the FDA's 2026 Human Foods Program priorities is raising attention on documentation and compliance quality. The FDA's recognition of niacinamide under 21 CFR 184.1535 also supports its established role in food-related applications. For the Niacinamide market, North America offers one of the clearest settings where stronger regulation and premium positioning support faster value growth.

Europe remains important because it brings stable regulatory frameworks and disciplined supplement and cosmetic channels to the Niacinamide market. The region's food fortification structure under EU regulation and its 2023 update on niacin forms show that the category remains actively governed rather than mature and static. Germany's Federal Institute for Risk Assessment has also proposed a maximum of 160 mg per day for nicotinamide in food supplements, which influences formulation discipline in the supplement channel.

1. Aurorium
2. Bactolac Pharmaceutical, Inc.
3. BASF
4. dsm-firmenich AG
5. Evonik Industries
6. Fagron
7. Foodchem International
8. Hubei Guangji Pharmaceutical Co., Ltd.
9. Jubilant Group
10. Kyowa Hakko Bio Co., Ltd.
11. Lasons India Pvt. Ltd.
12. Lonza Group
13. Merck
14. Shandong Hongda Biotechnology Co., Ltd.
15. Vanetta
16. Vertellus Holdings
17. Zhejiang Lanbo Biotechnology Co., Ltd.
18. Zhejiang NHU

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expanding Dermatology-Backed Skincare Adoption
  • 4.2.2 Growth in Pharmaceutically Positioned Niacinamide Use
  • 4.2.3 Food Fortification and Nutraceutical Label Expansion
  • 4.2.4 Capacity Expansion in Asia-Based Manufacturing Clusters
  • 4.2.5 Direct-to-Consumer Ingredient Storytelling and Clinical Claim Validation
  • 4.2.6 Supply-Chain De-Risking Through Multi-Sourcing and Regional Stocking
• 4.3 Market Restraints
  • 4.3.1 Price Pressure From Commodity-Grade Producers
  • 4.3.2 Formulation Stability and pH Compatibility Constraints
  • 4.3.3 Regulatory Fragmentation Across Cosmetic and Supplement Claims
  • 4.3.4 Substitution Risk From Alternative Barrier-Repair Actives
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Form
  • 5.1.1 Powder
  • 5.1.2 Granular
  • 5.1.3 Liquid
• 5.2 By Grade
  • 5.2.1 Pharmaceutical Grade
  • 5.2.2 Feed Grade
  • 5.2.3 Food Grade
  • 5.2.4 Cosmetic Grade
• 5.3 By Application
  • 5.3.1 Cosmetics and Personal Care
    • 5.3.1.1 Skincare Products
    • 5.3.1.2 Haircare Products
  • 5.3.2 Pharmaceuticals
    • 5.3.2.1 Vitamin Deficiency Treatment
    • 5.3.2.2 Cardiovascular Support
  • 5.3.3 Food and Beverages
  • 5.3.4 Human Nutrition
  • 5.3.5 Animal Nutrition
• 5.4 By End User
  • 5.4.1 Pharmaceutical Companies
  • 5.4.2 Cosmetic Manufacturers
  • 5.4.3 Food and Beverage Companies
  • 5.4.4 Nutraceutical Companies
  • 5.4.5 Animal Feed Producers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Aurorium
  • 6.3.2 Bactolac Pharmaceutical, Inc.
  • 6.3.3 BASF SE
  • 6.3.4 dsm-firmenich AG
  • 6.3.5 Evonik Industries AG
  • 6.3.6 Fagron NV
  • 6.3.7 Foodchem International Corporation
  • 6.3.8 Hubei Guangji Pharmaceutical Co., Ltd.
  • 6.3.9 Jubilant Life Sciences Limited
  • 6.3.10 Kyowa Hakko Bio Co., Ltd.
  • 6.3.11 Lasons India Pvt. Ltd.
  • 6.3.12 Lonza Group AG
  • 6.3.13 Merck KGaA
  • 6.3.14 Shandong Hongda Biotechnology Co., Ltd.
  • 6.3.15 Vanetta
  • 6.3.16 Vertellus Holdings LLC
  • 6.3.17 Zhejiang Lanbo Biotechnology Co., Ltd.
  • 6.3.18 Zhejiang NHU Co., Ltd.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment